338 related articles for article (PubMed ID: 34096329)
41. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.
Lombardi C; Comberiati P; Ridolo E; Cottini M; Yacoub MR; Casagrande S; Riccò M; Bottazzoli M; Berti A
Drugs; 2024 Jun; 84(6):661-684. PubMed ID: 38849701
[TBL] [Abstract][Full Text] [Related]
42. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
[TBL] [Abstract][Full Text] [Related]
43. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
Kupczyk M; Kuna P
Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
[TBL] [Abstract][Full Text] [Related]
44. Benralizumab: an updated treatment of eosinophilic asthma.
Cushen B; Menzies-Gow A
Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
[No Abstract] [Full Text] [Related]
45. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
46. Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE).
Contoli M; Santus P; Menzella F; Rocchi C; Radovanovic D; Baraldi F; Martelli C; Casanova S; Barbetta C; Micheletto C; Scichilone N; Beghè B; Carpagnano E; Papi A
Clin Transl Allergy; 2022 Apr; 12(4):e12143. PubMed ID: 35423001
[TBL] [Abstract][Full Text] [Related]
47. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
49. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
50. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
51. Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab.
Landi C; Cameli P; Vantaggiato L; Bergantini L; d'Alessandro M; Perruzza M; Carleo A; Shaba E; Di Giuseppe F; Angelucci S; Bargagli E; Bini L
Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140563. PubMed ID: 33176218
[TBL] [Abstract][Full Text] [Related]
52. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
53. Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.
Calzetta L; Ritondo BL; Matera MG; Facciolo F; Rogliani P
Br J Pharmacol; 2020 Oct; 177(20):4750-4765. PubMed ID: 32857420
[TBL] [Abstract][Full Text] [Related]
54. Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study.
Kurosawa M; Ogawa E; Sutoh E
Eur Ann Allergy Clin Immunol; 2019 Sep; 51(5):213-221. PubMed ID: 30983308
[No Abstract] [Full Text] [Related]
55. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
56. Subcutaneous Mepolizumab Injection: An Adjunctive Treatment for Recalcitrant Allergic Fungal Rhinosinusitis Patients With Asthma.
Karp J; Dhillon I; Panchmatia R; Javer A
Am J Rhinol Allergy; 2021 Mar; 35(2):256-263. PubMed ID: 32819148
[TBL] [Abstract][Full Text] [Related]
57. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study.
Vantaggiato L; Perruzza M; Refini RM; Bergantini L; d'Alessandro M; Cameli P; Perruzza D; Bini L; Bargagli E; Landi C
Lung; 2020 Oct; 198(5):761-765. PubMed ID: 32691140
[TBL] [Abstract][Full Text] [Related]
58. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
59. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.
Pavord ID; Menzies-Gow A; Buhl R; Chanez P; Dransfield M; Lugogo N; Keene ON; Bradford ES; Yancey SW
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1121-1132.e7. PubMed ID: 32889223
[TBL] [Abstract][Full Text] [Related]
60. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.
Cameli P; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Schroeder JW; Senna G; Vultaggio A; Benci M; Boarino S; Menzella F
J Asthma Allergy; 2024; 17():273-290. PubMed ID: 38562251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]